Low-density lipoproteinadsorber capable of simultaneously performing plasma separation and plasma adsorption

Abstract

The invention discloses a low-density lipoproteinadsorber capable of simultaneously performing plasma separation and plasma adsorption. The low-density lipoproteinadsorber comprises a housing, a bloodinlet, a blood outlet and a plasma outlet, wherein the blood inlet, the blood outlet and the plasma outlet are formed in the housing and communicated with the inside of the housing, and the inner cavity of the housing is provided with a separation cavity and an adsorption cavity; two ends of the inner cavity of the housing are provided with seal rings; hollow fibrous membrane is arranged in the separation cavity; two ends of the hollow fibrous membrane are inserted into and fixed to the seal rings and are communicated with the blood inlet and the blood outlet; the separation cavity and the adsorption cavity are communicated through first porous membrane only permitting plasma to permeate through; a low-density lipoproteinadsorption agent is arranged in the adsorption cavity. The low-density lipoproteinadsorber has the advantages that simultaneous performing of plasma separation and plasma adsorption can be achieved by arranging the separation cavity and the adsorption cavity, direct contact between blood cells and the adsorption agent is avoided, and the biocompatibility is improved; a regeneration treatment mode or single-time adsorption treatment mode can be selected by a patient according to his / her illnessstate by himself / herself; the consumable cost and treatment cost are reduced, and the adsorption effect is improved.

Description

technical field [0001] The invention relates to the field of medical devices, in particular to a low-density lipoprotein adsorber capable of simultaneously performing plasma separation and plasma adsorption. Background technique [0002] Low-density lipoprotein adsorbent is a filler of anti-low-density lipoprotein antibody-carrier complex, which couples anti-low-density lipoprotein antibody to the carrier matrix through the action of chemical bonds, and uses anti-low-density lipoprotein antibody to treat human body Selective binding of low-density lipoprotein for adsorption. The anti-low-density lipoprotein antibody here can also be other ligand molecules that have a specific recognition relationship with low-density lipoprotein, such as dextran sulfate, polyacrylic acid, etc. Low-density lipoprotein adsorption therapy is a new technology developed in recent decades, which is mainly used to treat refractory diseases with high low-density lipoprotein. [0003] Compared with ...

AI Technical Summary

Problems solved by technology

In this process, there are many devices connected in series, the operation of medical staff is difficult, and the amount of blood in extracorporeal circulation is large, and there are many medical devices in contact, which not only increases the physical burden of patients, but also causes problems such as hemolysis and coagulation. The probability of occurrence increases, which increases the safety risk during treatment

In addition, the cost of a complete set of plasma adsorption equipment is relatively high

The above-mentioned problems make it difficult for the traditional treatment mode of plasma separator plus low-density lipoprotein adsorption column to be widely promoted in China

[0005] Compared with plasma adsorption, whole blood adsorption can avoid excessive investment in equipment and consumables during treatment. However, whole blood adsorption has two obvious disadvantages

On the one hand, during the whole blood adsorption process, blood cells are in direct contact with the adsorption material, which is likely to cause immune reactions

On the other hand, because of its limited adsorption capacity, the adsorption of whole blood requires a larger volume of the adsorption column, generally 700mL or 1000mL (the volume of the plasma adsorption column is generally less than 350mL). If it is too large, it is easy to cause related adverse reactions

[0006] The patent with the publication number CN102631722B discloses a plasma separation adsorber capable of purifying blood, which can realize plasma separation and plasma adsorption at the same time. There are theoretical flaws and technical bottlenecks

First of all, on the one hand, the fibrous adsorbent is limited due to its specific area (the difference between the two is tens of times), and on the other hand, because of the short residence time of blood (the contact time between the adsorbent and blood) during the adsorption process, the fibrous adsorbent The adsorption capacity of the adsorbent is very limited and cannot meet the medical standards (especially for diseases caused by pathogenic substances such as high-abundance proteins in human blood, it is not enough); secondly, the manufacturing process of fibrous adsorbents is complicated and the technical requirements are high. Currently, fibrous adsorbents for medical use Adsorbents are basically in the laboratory stage. There are no fibrous adsorbent blood purification related products in China, and there is only Toraymyxin, a product from Japan’s Toray abroad, and this product can only be used for diseases caused by low-abundance pathogenic substances. , cannot be applied to indications corresponding to low-density lipoprotein adsorption, especially for severe patients

[0007] In addition, it should be pointed out that the adsorber disclosed by the patent with publication number CN102631722B is not partitioned, resulting in uneven adsorption of the fibrous adsorbent in the shell, resulting in unsatisfactory actual adsorption effect. Incomplete, further increasing patient treatment costs

Images